Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2A | P28223 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29365389 | 0.76 | HTR2A (0.41) | HTR2A | |
| SCHEMBL12983582 | 0.76 | HTR2A (0.41) | HTR2A | |
| SCHEMBL631657 | 0.74 | HTR2A (0.31) | HTR2A | |
| Iodide SCHEMBL29438714 | 0.74 | HTR2A (0.40) | HTR2A | |
| SCHEMBL3048014 | 0.73 | HTR2A (0.30) | HTR2A | |
| SCHEMBL3773580 | 0.73 | HTR2A (0.30) | HTR2A | |
| SCHEMBL3862739 | 0.73 | MAOA (0.32) | HTR2A | |
| SCHEMBL291732 | 0.73 | BRD4 (0.32) | HTR2A | |
| SCHEMBL1547704 | 0.73 | HTR2A (0.30) | HTR2A | |
| SCHEMBL8021483 | 0.70 | HTR6 (0.33) | HTR2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1703797-A4 | TRICYCLIC MODULATORS OF THE GLUCOCORTICOID RECEPTOR, AP-1, AND/OR NF-kappaB ACTIVITY AND USE THEREOF | BRISTOL MYERS SQUIBB CO (US) | 2009-01-14 | — | — | EP | claimed |
| EP-1534273-A4 | MODULATORS OF THE GLUCOCORTICOID RECEPTOR AND METHOD | BRISTOL MYERS SQUIBB CO (US) | 2007-08-22 | — | — | EP | claimed |
| EP-1703797-A2 | TRICYCLIC MODULATORS OF THE GLUCOCORTICOID RECEPTOR, AP-1, AND/OR NF-κB ACTIVITY AND USE THEREOF | Bristol-Myers Squibb Company (US) | 2006-09-27 | — | — | EP | claimed |
| WO-2005072132-A2 | TRICYCLIC MODULATORS OF THE GLUCOCORTICOID RECEPTOR, AP-1, AND/OR NF-κB ACTIVITY AND USE THEREOF | BRISTOL-MYERS SQUIBB COMPANY (US) | 2005-08-11 | — | — | WO | claimed |
| EP-1534273-A2 | MODULATORS OF THE GLUCOCORTICOID RECEPTOR AND METHOD | Bristol-Myers Squibb Company (US) | 2005-06-01 | — | — | EP | claimed |
| WO-2004009017-A2 | MODULATORS OF THE GLUCOCORTICOID RECEPTOR AND METHOD | BRISTOL-MYERS SQUIBB COMPANY (US) | 2004-01-29 | — | — | WO | claimed |
| EP-1703797-A4 | TRICYCLIC MODULATORS OF THE GLUCOCORTICOID RECEPTOR, AP-1, AND/OR NF-kappaB ACTIVITY AND USE THEREOF | BRISTOL MYERS SQUIBB CO (US) | 2009-01-14 | — | — | EP | disclosed |
| EP-1534273-A4 | MODULATORS OF THE GLUCOCORTICOID RECEPTOR AND METHOD | BRISTOL MYERS SQUIBB CO (US) | 2007-08-22 | — | — | EP | disclosed |
| EP-1703797-A2 | TRICYCLIC MODULATORS OF THE GLUCOCORTICOID RECEPTOR, AP-1, AND/OR NF-κB ACTIVITY AND USE THEREOF | Bristol-Myers Squibb Company (US) | 2006-09-27 | — | — | EP | disclosed |
| WO-2005072132-A2 | TRICYCLIC MODULATORS OF THE GLUCOCORTICOID RECEPTOR, AP-1, AND/OR NF-κB ACTIVITY AND USE THEREOF | BRISTOL-MYERS SQUIBB COMPANY (US) | 2005-08-11 | — | — | WO | disclosed |
| EP-1534273-A2 | MODULATORS OF THE GLUCOCORTICOID RECEPTOR AND METHOD | Bristol-Myers Squibb Company (US) | 2005-06-01 | — | — | EP | disclosed |
| WO-2004009017-A2 | MODULATORS OF THE GLUCOCORTICOID RECEPTOR AND METHOD | BRISTOL-MYERS SQUIBB COMPANY (US) | 2004-01-29 | — | — | WO | disclosed |